Overview

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.
Phase:
Phase 2
Details
Lead Sponsor:
Centaur Pharmaceuticals